OTC Markets OTCPK - Delayed Quote USD
Dimerix Limited (SBMJF)
0.2500
0.0000
(0.00%)
As of April 23 at 4:00:00 PM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, MBA, Ph.D. | CEO, MD & Director | 414.27k | -- | -- |
| Dr. David Everett Fuller BPharm, M.D., MBBS | Chief Medical Officer | 206.27k | -- | 1964 |
| Mr. Robert Shepherd | Chief Commercialisation Officer | 219.6k | -- | -- |
| Mr. Hamish George B.Com., C.A. | CFO & Company Secretary | -- | -- | -- |
| Mr. Kevin Donald George Pfleger BA (Hons), MA, Ph.D. | Chief Scientific Advisor | -- | -- | -- |
Dimerix Limited
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.
Corporate Governance
Dimerix Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
July 21, 2025 at 4:45 AM UTC - July 25, 2025 at 4:45 AM UTC
Dimerix Limited Earnings Date
Recent Events
Recent Events Information Not Available
Related Tickers
BEIGF BeiGene, Ltd.
15.95
-16.10%
EGTX.ST Egetis Therapeutics AB (publ)
3.9000
-1.02%
DRTS Alpha Tau Medical Ltd.
2.6400
-0.38%
DSGN Design Therapeutics, Inc.
4.2500
+4.42%
VRCA Verrica Pharmaceuticals Inc.
0.4651
+1.40%
FHTX Foghorn Therapeutics Inc.
4.4500
-4.91%
SLN Silence Therapeutics plc
3.5100
+5.71%
ALXO ALX Oncology Holdings Inc.
0.6065
+4.57%
KRYS Krystal Biotech, Inc.
169.06
+1.97%
CMPX Compass Therapeutics, Inc.
2.1200
+2.42%